Shanghai Cancer Hospital, China clinical trials
Shanghai Cancer Hospital, China is the lead sponsor of 3 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Almonertinib. The most-studied condition is Leptomeningeal Metastasis.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Shanghai Cancer Hospital, China
3 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
NCT06901817 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis
|
Phase 2 | Recruiting | 2025-03 | China |
|
Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
NCT04522687 · ClinicalTrials.gov ↗ · NSCLC, Esophageal Squamous Cell Carcinoma, Thymic Epithelial Tumor
|
Observational | Recruiting | 2012-01 | China |
|
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
NCT05800223 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Metastatic
Drug: Almonertinib |
Phase 3 | Recruiting | 2023-01 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Shanghai Cancer Hospital, China trials
1 compoundDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Shanghai Cancer Hospital, China trials
5 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Leptomeningeal Metastasis
| Sponsor | Trials |
|---|---|
| Guangzhou Medical University | 6 |
| Cerenome | 1 |
Sponsors with the most current trials registered for this condition.
Questions about Shanghai Cancer Hospital, China trials
How many clinical trials does Shanghai Cancer Hospital, China sponsor?
Shanghai Cancer Hospital, China is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.
Are Shanghai Cancer Hospital, China trials recruiting?
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Shanghai Cancer Hospital, China testing?
Its current trials name 1 drug or biological as interventions. The most frequent are Almonertinib (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.